Revisiting CYP2C9-Mediated drug-drug Interactions: A Review
Drug-drug interactions (DDI) are the most common cases that occur in our healthcare in which are very alarming as it may lead to severe complications. Consumption of natural products concomitantly with conventional drugs or treatment using polypharmacy have become the norm that promoting the potenti...
Gespeichert in:
| Veröffentlicht in: | Research journal of pharmacy and technology 2021-11, Vol.14 (11), p.6166-6172 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6172 |
|---|---|
| container_issue | 11 |
| container_start_page | 6166 |
| container_title | Research journal of pharmacy and technology |
| container_volume | 14 |
| creator | Abd Mutalib, Nurliana Ariffin Mohd Rafi, Mohd Amirul Abd Latip, Normala |
| description | Drug-drug interactions (DDI) are the most common cases that occur in our healthcare in which are very alarming as it may lead to severe complications. Consumption of natural products concomitantly with conventional drugs or treatment using polypharmacy have become the norm that promoting the potential of pharmacokinetic or pharmacodynamic drug interactions as the combination may mimic, increase or reduce the effects of the drug or the herb which could result in clinically significant interactions. CYP2C9 is the second major isoform from CYP450 family of enzyme, which responsible in phase 1 metabolism of 15-20% clinical drugs. Up to date, many substrates of CYP2C9 have been discovered and these discoveries may open more doors for potential drug-drug interactions in patients. Many studies have been done to evaluate the effect of drugs on the activity of CYP2C9 and how it influenced the effectiveness of therapy in patients. Various data regarding CYP2C9 related DDI from in vitro, in vivo and clinical studies were critically discussed in this review to provide insights on how these drugs and natural products may exhibit drug interactions clinically. This review could be beneficial reference material for health practitioners and researchers. |
| doi_str_mv | 10.52711/0974-360X.2021.01068 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2671716944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2671716944</sourcerecordid><originalsourceid>FETCH-LOGICAL-c144t-6b6622455701aee36576b0502c1a7fccfe3e6e65a69f18c05a88f3ee95c5a1943</originalsourceid><addsrcrecordid>eNo9kG9LwzAQxoMoOOY-glDwdWcuTS6pvhrFP4OJIgr6KmTpdXRoO5NW8du7brJ78dxxPPcc_Bg7Bz5VQgNc8lzLNEP-NhVcwJQDR3PERof18WEGc8omMa75ttAoIc2IXT_Tdx3rrm5WSfH-JIo8faCydh2VSRn6VTpIMm86Cs53ddvEq2SWDEf0c8ZOKvcRafLfx-z19ualuE8Xj3fzYrZIPUjZpbhEFEIqpTk4ogyVxiVXXHhwuvK-ooyQUDnMKzCeK2dMlRHlyisHuczG7GKfuwntV0-xs-u2D832pRWoQQPmcnCpvcuHNsZAld2E-tOFXwvc7lDZgYMdmNgBld2hyv4AM9lZwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2671716944</pqid></control><display><type>article</type><title>Revisiting CYP2C9-Mediated drug-drug Interactions: A Review</title><source>EZB Electronic Journals Library</source><creator>Abd Mutalib, Nurliana ; Ariffin Mohd Rafi, Mohd Amirul ; Abd Latip, Normala</creator><creatorcontrib>Abd Mutalib, Nurliana ; Ariffin Mohd Rafi, Mohd Amirul ; Abd Latip, Normala</creatorcontrib><description>Drug-drug interactions (DDI) are the most common cases that occur in our healthcare in which are very alarming as it may lead to severe complications. Consumption of natural products concomitantly with conventional drugs or treatment using polypharmacy have become the norm that promoting the potential of pharmacokinetic or pharmacodynamic drug interactions as the combination may mimic, increase or reduce the effects of the drug or the herb which could result in clinically significant interactions. CYP2C9 is the second major isoform from CYP450 family of enzyme, which responsible in phase 1 metabolism of 15-20% clinical drugs. Up to date, many substrates of CYP2C9 have been discovered and these discoveries may open more doors for potential drug-drug interactions in patients. Many studies have been done to evaluate the effect of drugs on the activity of CYP2C9 and how it influenced the effectiveness of therapy in patients. Various data regarding CYP2C9 related DDI from in vitro, in vivo and clinical studies were critically discussed in this review to provide insights on how these drugs and natural products may exhibit drug interactions clinically. This review could be beneficial reference material for health practitioners and researchers.</description><identifier>ISSN: 0974-3618</identifier><identifier>EISSN: 0974-360X</identifier><identifier>EISSN: 0974-306X</identifier><identifier>DOI: 10.52711/0974-360X.2021.01068</identifier><language>eng</language><publisher>Raipur: A&V Publications</publisher><subject>Antibiotics ; Anticoagulants ; Anticonvulsants ; Bacterial infections ; Convulsions & seizures ; Drug dosages ; Drug interactions ; Enzymes ; Infections ; Metabolism ; Metabolites ; Migraine ; Natural products ; Reference materials</subject><ispartof>Research journal of pharmacy and technology, 2021-11, Vol.14 (11), p.6166-6172</ispartof><rights>Copyright A&V Publications Nov 2021</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c144t-6b6622455701aee36576b0502c1a7fccfe3e6e65a69f18c05a88f3ee95c5a1943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids></links><search><creatorcontrib>Abd Mutalib, Nurliana</creatorcontrib><creatorcontrib>Ariffin Mohd Rafi, Mohd Amirul</creatorcontrib><creatorcontrib>Abd Latip, Normala</creatorcontrib><title>Revisiting CYP2C9-Mediated drug-drug Interactions: A Review</title><title>Research journal of pharmacy and technology</title><description>Drug-drug interactions (DDI) are the most common cases that occur in our healthcare in which are very alarming as it may lead to severe complications. Consumption of natural products concomitantly with conventional drugs or treatment using polypharmacy have become the norm that promoting the potential of pharmacokinetic or pharmacodynamic drug interactions as the combination may mimic, increase or reduce the effects of the drug or the herb which could result in clinically significant interactions. CYP2C9 is the second major isoform from CYP450 family of enzyme, which responsible in phase 1 metabolism of 15-20% clinical drugs. Up to date, many substrates of CYP2C9 have been discovered and these discoveries may open more doors for potential drug-drug interactions in patients. Many studies have been done to evaluate the effect of drugs on the activity of CYP2C9 and how it influenced the effectiveness of therapy in patients. Various data regarding CYP2C9 related DDI from in vitro, in vivo and clinical studies were critically discussed in this review to provide insights on how these drugs and natural products may exhibit drug interactions clinically. This review could be beneficial reference material for health practitioners and researchers.</description><subject>Antibiotics</subject><subject>Anticoagulants</subject><subject>Anticonvulsants</subject><subject>Bacterial infections</subject><subject>Convulsions & seizures</subject><subject>Drug dosages</subject><subject>Drug interactions</subject><subject>Enzymes</subject><subject>Infections</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Migraine</subject><subject>Natural products</subject><subject>Reference materials</subject><issn>0974-3618</issn><issn>0974-360X</issn><issn>0974-306X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo9kG9LwzAQxoMoOOY-glDwdWcuTS6pvhrFP4OJIgr6KmTpdXRoO5NW8du7brJ78dxxPPcc_Bg7Bz5VQgNc8lzLNEP-NhVcwJQDR3PERof18WEGc8omMa75ttAoIc2IXT_Tdx3rrm5WSfH-JIo8faCydh2VSRn6VTpIMm86Cs53ddvEq2SWDEf0c8ZOKvcRafLfx-z19ualuE8Xj3fzYrZIPUjZpbhEFEIqpTk4ogyVxiVXXHhwuvK-ooyQUDnMKzCeK2dMlRHlyisHuczG7GKfuwntV0-xs-u2D832pRWoQQPmcnCpvcuHNsZAld2E-tOFXwvc7lDZgYMdmNgBld2hyv4AM9lZwg</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Abd Mutalib, Nurliana</creator><creator>Ariffin Mohd Rafi, Mohd Amirul</creator><creator>Abd Latip, Normala</creator><general>A&V Publications</general><scope>AAYXX</scope><scope>CITATION</scope><scope>04Q</scope><scope>04S</scope><scope>04W</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20211101</creationdate><title>Revisiting CYP2C9-Mediated drug-drug Interactions: A Review</title><author>Abd Mutalib, Nurliana ; Ariffin Mohd Rafi, Mohd Amirul ; Abd Latip, Normala</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c144t-6b6622455701aee36576b0502c1a7fccfe3e6e65a69f18c05a88f3ee95c5a1943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibiotics</topic><topic>Anticoagulants</topic><topic>Anticonvulsants</topic><topic>Bacterial infections</topic><topic>Convulsions & seizures</topic><topic>Drug dosages</topic><topic>Drug interactions</topic><topic>Enzymes</topic><topic>Infections</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Migraine</topic><topic>Natural products</topic><topic>Reference materials</topic><toplevel>online_resources</toplevel><creatorcontrib>Abd Mutalib, Nurliana</creatorcontrib><creatorcontrib>Ariffin Mohd Rafi, Mohd Amirul</creatorcontrib><creatorcontrib>Abd Latip, Normala</creatorcontrib><collection>CrossRef</collection><collection>India Database</collection><collection>India Database: Business</collection><collection>India Database: Science & Technology</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Research journal of pharmacy and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abd Mutalib, Nurliana</au><au>Ariffin Mohd Rafi, Mohd Amirul</au><au>Abd Latip, Normala</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Revisiting CYP2C9-Mediated drug-drug Interactions: A Review</atitle><jtitle>Research journal of pharmacy and technology</jtitle><date>2021-11-01</date><risdate>2021</risdate><volume>14</volume><issue>11</issue><spage>6166</spage><epage>6172</epage><pages>6166-6172</pages><issn>0974-3618</issn><eissn>0974-360X</eissn><eissn>0974-306X</eissn><abstract>Drug-drug interactions (DDI) are the most common cases that occur in our healthcare in which are very alarming as it may lead to severe complications. Consumption of natural products concomitantly with conventional drugs or treatment using polypharmacy have become the norm that promoting the potential of pharmacokinetic or pharmacodynamic drug interactions as the combination may mimic, increase or reduce the effects of the drug or the herb which could result in clinically significant interactions. CYP2C9 is the second major isoform from CYP450 family of enzyme, which responsible in phase 1 metabolism of 15-20% clinical drugs. Up to date, many substrates of CYP2C9 have been discovered and these discoveries may open more doors for potential drug-drug interactions in patients. Many studies have been done to evaluate the effect of drugs on the activity of CYP2C9 and how it influenced the effectiveness of therapy in patients. Various data regarding CYP2C9 related DDI from in vitro, in vivo and clinical studies were critically discussed in this review to provide insights on how these drugs and natural products may exhibit drug interactions clinically. This review could be beneficial reference material for health practitioners and researchers.</abstract><cop>Raipur</cop><pub>A&V Publications</pub><doi>10.52711/0974-360X.2021.01068</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0974-3618 |
| ispartof | Research journal of pharmacy and technology, 2021-11, Vol.14 (11), p.6166-6172 |
| issn | 0974-3618 0974-360X 0974-306X |
| language | eng |
| recordid | cdi_proquest_journals_2671716944 |
| source | EZB Electronic Journals Library |
| subjects | Antibiotics Anticoagulants Anticonvulsants Bacterial infections Convulsions & seizures Drug dosages Drug interactions Enzymes Infections Metabolism Metabolites Migraine Natural products Reference materials |
| title | Revisiting CYP2C9-Mediated drug-drug Interactions: A Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T16%3A05%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Revisiting%20CYP2C9-Mediated%20drug-drug%20Interactions:%20A%20Review&rft.jtitle=Research%20journal%20of%20pharmacy%20and%20technology&rft.au=Abd%20Mutalib,%20Nurliana&rft.date=2021-11-01&rft.volume=14&rft.issue=11&rft.spage=6166&rft.epage=6172&rft.pages=6166-6172&rft.issn=0974-3618&rft.eissn=0974-360X&rft_id=info:doi/10.52711/0974-360X.2021.01068&rft_dat=%3Cproquest_cross%3E2671716944%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2671716944&rft_id=info:pmid/&rfr_iscdi=true |